Halogenated thymidine analogues restore the expression of silenced genes without demethylation

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6927-6933

  Fan, Jun ^a   Kodama, Ei Ichi ^a   Koh, Yasuhiro ^b   Nakao, Mitsuyoshi ^c   Matsuoka, Masao ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BISULFITE; BROXURIDINE; CLOXURIDINE; DNA; GLUTATHIONE TRANSFERASE; HALIDE; HISTONE H3; IDOXURIDINE; LUCIFERASE; RETROVIRUS VECTOR; THYMIDINE DERIVATIVE; TRICHOSTATIN A;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN K 562; CELL STRAIN MCF 7; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BROMODEOXYURIDINE; CELL LINE, TUMOR; CPG ISLANDS; DNA; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC VECTORS; HISTONES; HUMANS; HYDROCARBONS, HALOGENATED; K562 CELLS; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; THYMIDINE;

EID: 23044516024     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3495     Document Type: Article

References (39)

1. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999;99:451-4.
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
3. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415-28.
5. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63.
6. Issa JP. Decitabine. Curr Opin Oncol 2003;15:446-51.
7. Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene repression. Eur J Biochem 2001;268:1-6.
8. Slack A, Bovenzi V, Bigey P, et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 2002; 4:381-9.
9. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of MBD2 suppresses intestinal tumorigenesis. Nat Genet 2003;34:145-7.
10. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
11. Kantaijian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003;98:522-8.
12. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002;13: 1699-716.
13. Hurd PJ, Whitmarsh AJ, Baldwin GS, et al. Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 1999; 286:389-401.
14. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003;95:399-409.
15. Cheng JC, Weisenberger DJ, Gonzales FA, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004;24:1270-8.
16. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18:1357-63.
17. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
18. Chou J. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chou TC, Rideout DC, editors. Synergism and antagonism in chemotherapy. San Diego (CA): Academic Press: 1991. p. 223-44.
19. Nosaka K, Maeda M, Tamiya S, Sakai T, Mitsuya H, Matsuoka M. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res 2000;60:1043-8.
20. Wang L, Groves MJ, Hepburn MD, Bowen DT. Glutathione S-transferase enzyme expression in hematopoietic cell lines implies a differential protective role for T1 and A1 isoenzymes in erythroid and for M1 in lymphoid lineages. Haematologica 2000;85:573-9.
21. Mutskov V, Felsenfeld G, Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23:138-49.
22. Ohki I, Shimotake N, Fujita N, et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 2001; 105:487-97.
23. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 2003;31:1765-74.
24. Hino S, Fan J, Taguwa S, Akasaka K, Matsuoka M. Sea urchin insulator protects lentiviral vector from silencing by maintaining active chromatin structure. Gene Ther 2004;11:819-28.
25. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
26. Lin X, Nelson WG. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 2003;63:498-504.
27. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002;108:489-500.
28. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393: 386-9.
29. Dillon N, Festenstein R. Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet 2002;18:252-8.
30. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-60.
31. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 2002;62: 6456-61.
32. McInerney JM, Nawrocki JR, Lowrey CH. Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine. Gene Ther 2000;7: 653-63.
33. Singer J, Stellwagen RH, Roberts-Ems J, Riggs AD. 5-Methylcytosine content of rat hepatoma DNA substituted with bromodeoxyuridine. J Biol Chem 1977;252: 5509-13.
34. Schwartz SA. Transcriptional activation of endogenous rat retrovirus with and without hypomethylation of proviral DNA. Biochem Biophys Res Commun 1983; 112:571-7.
35. Hutchins AS, Mullen AC, Lee HW, et al. Gene silencing quantitatively controls the function of a developmental trans-activator. Mol Cell 2002;10:81-91.
36. Lembo F, Pero R, Angrisano T, et al. MBDin, a novel MBD2-interacting protein, relieves MBD2 repression potential and reactivates transcription from methylated promoters. Mol Cell Biol 2003;23:1656-65.
37. Amedeo P, Habu Y, Afsar K, Scheid OM, Paszkowski J. Disruption of the plant gene MOM releases transcriptional silencing of methylated genes. Nature 2000;405: 203-6.
38. Fasy TM, Cullen BR, Luk D, Bick MD. Studies on the enhanced interaction of halodeoxyuridine-substituted DNAs with H1 histones and other polypeptides. J Biol Chem 1980;255:1380-7.
39. Graves BJ, Eisenman RN, McKnight SL. Delineation of transcriptional control signals within the Moloney murine sarcoma virus long terminal repeat. Mol Cell Biol 1985;5:1948-58.